• CXS Corporate Presentation November 2009 
  (PDF, format, 506 KB)

Oral presentations from the 51st American Society of Hematology (ASH) Orlando December 5-8 2009.

• Safety and Efficacy of Subcutaneous- Adminitered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia  Patients Who Harbor the Bcr-Abl T315I Mutation - Results of an Ongoing Multicenter Phase2/3 Study
  J Cortes, HJ Khoury, F Nicolini, S Corm, J Lipton,
  D Jones, A Hochhaus, A Craig, A Benichou, E
  Humphriss, H Kantarjian
• Safety and Efficacy of Subcutaneous-Administered Omacetaxine
  Mepesuccinate in Chronic Myeloid Leukemia Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study
  J Cortes, D Raghunadharao, P Parikh, M Wetzler,
  J Lipton, D Jones, A Hochhaus, H Kantarjian, A
  Craig, A Benichou, E Humphriss and F Nicolini